drugset / Trial / NCT01208090
ACT-128800 in Patients With Moderate to Severe Chronic Plaque Psoriasis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study will assess the efficacy, safety and tolerability of two doses of ACT 128800 in patients with moderate-to-severe chronic plaque psoriasis.
Timeline
- Start
- 2010-10-31
- Primary completion
- 2012-10-31
- Completion
- 2012-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ponesimod | Small molecule | 20 mg | Oral |
| Subject | Ponesimod | Small molecule | 40 mg | Oral |